TY - JOUR
T1 - Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
AU - Veronese, Nicola
AU - Demurtas, Jacopo
AU - Yang, Lin
AU - Tonelli, Roberto
AU - Barbagallo, Mario
AU - Lopalco, Pierluigi
AU - Lagolio, Erik
AU - Celotto, Stefano
AU - Pizzol, Damiano
AU - Zou, Liye
AU - Tully, Mark A.
AU - Ilie, Petre Cristian
AU - Trott, Mike
AU - López-Sánchez, Guillermo F.
AU - Smith, Lee
PY - 2020/4/24
Y1 - 2020/4/24
N2 - The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition.
AB - The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition.
KW - ARDS
KW - COVID-19
KW - Coronavirus
KW - Corticosteroids
KW - Methylprednisolone
KW - Pneumonia
KW - SARS-Cov-2
UR - https://pure.ulster.ac.uk/en/publications/use-of-corticosteroids-in-coronavirus-disease-2019-pneumonia-a-sy
UR - http://www.scopus.com/inward/record.url?scp=85084836183&partnerID=8YFLogxK
UR - https://www.frontiersin.org/article/10.3389/fmed.2020.00170
U2 - 10.3389/fmed.2020.00170
DO - 10.3389/fmed.2020.00170
M3 - Article
C2 - 32391369
SN - 2296-858X
VL - 7
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 170
ER -